Provided by Tiger Trade Technology Pte. Ltd.

Charles River Laboratories

278.26
+5.261.93%
Post-market: 278.260.00000.00%19:30 EDT
Volume:767.56K
Turnover:213.40M
Market Cap:13.28B
PE:-57.00
High:280.40
Open:276.01
Low:275.63
Close:273.00
52wk High:303.31
52wk Low:144.26
Shares:47.74M
Float Shares:47.20M
Volume Ratio:1.05
T/O Rate:1.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.8814
EPS(LYR):-2.9122
ROE:-7.52%
ROA:4.11%
PB:4.68
PE(LYR):-95.55

Loading ...

Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV) and Charles River Labs (CRL)

TIPRANKS
·
May 09

These Analysts Increase Their Forecasts On Charles River After Better-Than-Expected Q1 Results

Benzinga Earnings
·
May 08

Charles River Labs Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
May 08

Charles River price target raised to $220 from $210 at Barclays

TIPRANKS
·
May 08

Barclays Reaffirms Their Buy Rating on Charles River Labs (CRL)

TIPRANKS
·
May 08

U.S. RESEARCH ROUNDUP-Applied Materials, McDonald's, McKesson

Reuters
·
May 08

Charles River Laboratories International Inc : Baird Raises Target Price to $213 From $200

THOMSON REUTERS
·
May 08

Charles River Laboratories International Inc : JP Morgan Raises Target Price to $180 From $160

THOMSON REUTERS
·
May 08

Charles River Laboratories International Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 08

Charles River Exec Says Any Decision to Expand China Structure Will Be Based on Cost, Demand, Growth Rates and Geopolitical Considerations

THOMSON REUTERS
·
May 07

Charles River Exec Says Recent Increase in Biopharma M&a Activity Has Provided Additional Source of Capital Infusion and Exit Strategy for Biotechs

THOMSON REUTERS
·
May 07

Charles River Exec Says Demand From Start-up Biotechs Remains Tepid as Earlier Stage and Seed Funding Environment Remains Constrained

THOMSON REUTERS
·
May 07

Charles River Exec Says Improved Demand in China Seen as Indication That Chinese Market Is Rebounding and Accelerating

THOMSON REUTERS
·
May 07

Charles River Exec Says Co Closely Monitoring China Market Given Accelerated Drug Innovation and in-Licensing Activity but Also Looking at Geopolitical Risks

THOMSON REUTERS
·
May 07

Charles River Exec Says Government Funding Pressures at Nih Have Modestly Impacted Client Spending

THOMSON REUTERS
·
May 07

Charles River Exec Says Revenue From Global Biopharmaceutical Client Segment Increased in the First Quarter - Conf Call

THOMSON REUTERS
·
May 07

Charles River beats quarterly estimates on steady demand for drug development services

Reuters
·
May 07

GUIDANCE: (CRL) Charles River Laboratories International Expects 2026 Non-GAAP EPS Range $10.80 - $11.30, vs. FactSet Est of $11.08

MT Newswires Live
·
May 07

Charles River Q1 Adjusted EPS USD 2.06 Vs. IBES Estimate USD 1.94

Reuters
·
May 07

Charles River Q1 revenue and adjusted EPS beat estimates

Reuters
·
May 07